Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Feb. 11, 2025 — Scientists have developed an innovative method for growing brain tumors of individual patients in the laboratory that mimic the original structure and the molecular property of ...

Researchers have now discovered that what we call the 'dessert stomach' is rooted in the brain. The same nerve cells that make us feel full after a meal ... Feb. 26, 2025 — Researchers have ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

These symptoms, which affect your ability to think, are often collectively described as “brain fog”, a non-medical, colloquial term. There are many potential causes of “brain fog”, but one ...

Regeneron, meanwhile, also has designs on the category with its CD20xCD3 bispecific odronextamab, which began a priority review at the FDA last October as a third-line treatment for DLBCL and for ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden ...